Company Filing History:
Years Active: 2021
Title: Meghan C. Langley: Innovator in Drug Responsive Domains
Introduction
Meghan C. Langley is a prominent inventor based in Stoughton, MA (US). She has made significant contributions to the field of biotechnology, particularly in the development of drug responsive domains. Her innovative work focuses on enhancing the stability of therapeutic proteins, which has important implications for medical treatments.
Latest Patents
Meghan holds 1 patent for her invention titled "CA2 compositions and methods for tunable regulation." This patent provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (IL15) payloads. The compositions and methods outlined in her patent offer new avenues for therapeutic applications.
Career Highlights
Meghan is currently employed at Obsidian Therapeutics, Inc., where she continues to push the boundaries of innovation in biotechnology. Her work at the company is characterized by a commitment to developing advanced therapeutic solutions that can significantly improve patient outcomes.
Collaborations
Throughout her career, Meghan has collaborated with talented individuals such as Kutlu Goksu Elpek and Dhruv Kam Sethi. These partnerships have fostered a collaborative environment that enhances the research and development process.
Conclusion
Meghan C. Langley is a trailblazer in the field of biotechnology, with a focus on drug responsive domains that have the potential to revolutionize therapeutic approaches. Her contributions are paving the way for future innovations in medical treatments.